Expression of p21 Cell Cycle Protein Is An Independent Predictor of Response to Salvage Radiotherapy after Radical Prostatectomy

Prostate

Volumn 58, Issue 3, 2004, Pages 269-276

  Rigaud, Jérôme ^a   Tiguert, Rabi ^a   Decobert, Marc ^a   Hovington, Hélène ^a   Latulippe, Eva ^b   Laverdiere, Jacques ^b   Larue, Hélène ^a   Lacombe, Louis ^a   Fradet, Yves ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

p21; p27; p53; Prognosis; Prostate cancer; PSA; Radical prostatectomy; Salvage radiotherapy

Indexed keywords

CELL CYCLE PROTEIN; FORMALDEHYDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN LOCALIZATION; SCORING SYSTEM; SURVIVAL TIME;

AGED; ANDROGEN ANTAGONISTS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0842327810     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10329     Document Type: Article

References (30)

1. Zincke H, Blute ML, Fallen MJ, Farrow GM. Radical prostatectomy for stage A adenocarcinoma of the prostate: Staging errors and their implications for treatment recommendations and disease outcome. J Urol 1991;146(4):1053-1058.
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 2000;164(1):101-105.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
4. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163(3):845-850.
5. Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: Analysis of efficacy and prognostic factors. Urology 2002;59(5):726-731.
6. Vanuytsel L, Janssens G, Van Poppel H, Rijnders A, Baert L. Radiotherapy for PSA recurrence after radical prostatectomy. Eur Urol 2001;39(4):425-429.
7. Gartel AL, Tyner AL. Transcriptional regulation of the p21 ((WAF1/CIP1)) gene. Exp Cell Res 1999;246(2):280-289.
8. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1(8):639-649.
9. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-423.
10. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002;15(1):35-44.
11. Oxley JD, Winkler MH, Parry K, Brewster S, Abbott C, Gillatt DA. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 2002;89(1):27-32.
12. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 1999;5(8):2082-2088.
13. Rakozy C, Grignon DJ, Li Y, Gheiler E, Gururajanna B, Pontes JE, Sakr W, Wood DP Jr, Sarkar FH. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: A molecular and immunohistochemical analysis. Pathol Res Pract 1999;195(3):129-135.
14. Ritter MA, Gilchrist KW, Voytovich M, Chappell RJ, Verhoven BM. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2002;53(3):574-580.
15. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997;3(12 Pt 1):2269-2274.
16. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90(12):916-920.
17. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159(3):941-945.
18. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, Van Der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000;164(6):2156-2161.
19. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999;39(1):8-15.
20. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 2001;95(3):135-139.
21. Sarkar FH, Li Y, Sakr WA, Grignon DJ, Madan SS, Wood DP Jr, Adsay V. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 1999;40(4):256-260.
22. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwic DG. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000;6(5):1896-1899.
23. Wang YA, Elson A, Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997;94(26):14590-14595.
24. Wang Y, Blandino G, Givol D. Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 1999;18(16):2643-2649.
25. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997;57(21):4703-4706.
26. Downing SR, Jackson P, Russell PJ. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: A review of the evidence. Urol Oncol 2001;6(3):103-110.
27. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 1996;48(6):971-979.
28. Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E, Cardesa A. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999;187(5):563-566.
29. Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAF-1) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 2001;49(3):191-199.
30. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL. Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002;8(3):775-781.